Eli Lilly and Co. and Sarah Cannon Research Institute (SCRI) entered a strategic partnership to co‑develop an investigational Phase II oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. “Lilly has a long history of leading innovation in cancer therapy with the goal to offer patients improved treatment outcomes,” said Christopher A...